Eledon Pharmaceuticals (ELDN) Return on Capital Employed (2014 - 2026)

Eledon Pharmaceuticals has reported Return on Capital Employed for 13 years, with the latest figure at 57.45% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 4833.0% year-over-year to 57.45%; the trailing twelve-month figure through Mar 2026 stood at 57.45% (down 4833.0% YoY), and the FY2025 full-year result was 29.43%, down 2326.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 57.45%, down from 19.01% in the prior quarter.
• The five-year high for Return on Capital Employed was 5.27% in Q1 2022, with the low at 57.45% in Q1 2026.
• Historically, Return on Capital Employed has averaged 21.0% across 5 years, with a median of 20.36% in 2023.
• Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 2201 bps — and 2026, when it sank 4833 bps.
• Eledon Pharmaceuticals' Return on Capital Employed stood at 16.1% in 2022, then slumped by 71 bps to 27.6% in 2023, then soared by 80 bps to 5.59% in 2024, then slumped by 240 bps to 19.01% in 2025, then tumbled by 202 bps to 57.45% in 2026.
• The last three Return on Capital Employed figures came in at 57.45% (Q1 2026), 19.01% (Q3 2025), and 17.82% (Q2 2025), per Business Quant data.